Prospective Study on the Efficacy and Safety of 2 Week or 3 Week Xelox Regimen for Adjuvant Chemotherapy in CRC
Status:
Completed
Trial end date:
2021-08-24
Target enrollment:
Participant gender:
Summary
This study select the diagnosis of postoperative colorectal cancer patients with stage II/III
to adjuvant chemotherapy, and received 2 weeks and 3 weeks xelox adjuvant treatment process
until disease progression or patients died or lost to follow-up. To analyze the difference in
efficacy and safety of xelox in 2 weeks and 3 weeks of postoperative adjuvant therapy for
colorectal cancer, so as to find a better postoperative adjuvant treatment model.